Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with oritavancin may decrease the plasma concentrations and therapeutic effects drugs that are substrates of CYP450 3A4 and/or 2D6. The proposed mechanism is increased clearance due to oritavancin-mediated induction of these isoenzymes. In a screening drug interaction study in 16 healthy volunteers, a single 1,200 mg dose of oritavancin decreased midazolam systemic exposure (AUC) by 18% and the urinary dextromethorphan-to-dextrorphan ratio by 31%, indicating weak induction of CYP450 3A4 and 2D6, respectively.

MANAGEMENT: Caution is advised when oritavancin used concomitantly with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly sensitive substrates or those for which minimal concentration changes may lead to therapeutic failure. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oritavancin is added to or withdrawn from therapy. Individual product labeling for the CYP450 3A4 and/or 2D6 substrate(s) should be consulted for further guidance.

Mavorixafor should be taken on an empty stomach after an overnight fast, 30 minutes before food. Do not consume grapefruit products during treatment with mavorixafor unless otherwise directed by your doctor. Grapefruit juice can increase the blood levels and adverse effects of mavorixafor, increasing the risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.